Consistent with our results, HNRNPA2B1 has been reported to act as an oncogene in breast cancer, pancreatic cancer, lung cancer, hepatocellular carcinoma, and cervical cancer (34, 40–43), while METTL14 functions as a suppressor gene in glioma and breast cancer (44, 45). The gene discussed is METTL14; the disease is hepatocellular carcinoma.